Résultats de la recherche

ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways AIM2 and NLRP3 inflammasome activation leads to development of atherosclerotic lesions in diabetic mice.